JP MORGAN/CALL/ELI LILLY & CO/740/0.01/17.01.25 | Market Closed - Börse Stuttgart 04:46:32 2024-06-18 am EDT | ||
| 1.8 EUR | +2.86% |
|
| Current month | +36.36% | ||
| 1 month | +78.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 1.8 | +2.86% |
| 24-06-17 | 1.75 | -2.78% |
| 24-06-14 | 1.8 | +9.09% |
| 24-06-13 | 1.65 | -1.20% |
| 24-06-12 | 1.67 | -8.74% |
Delayed Quote Börse Stuttgart
Last update June 18, 2024 at 04:46 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK27UW |
| ISIN | DE000JK27UW0 |
| Date issued | 2024-02-08 |
| Strike | 740 $ |
| Maturity | 2025-01-17 (213 Days) |
| Parity | 100 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.83 € |
|---|---|
| Lowest since issue | 0.82 € |
| Spread | 0.02 € |
| Spread % | 1.09% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Warrants
- Warrant
